Subcutaneous injections: These use shorter, thinner needles (ranging from 0.5 to 5/8 inches), as they only need to reach the fatty layer beneath the skin
Concentration clarity, carrier compatibility, finished-product presentation, documentation, labeling accuracy, and storage expectations all matter
Specific compatibility considerations include confirmation of absence of reducing agents for disulphide-containing peptides, BSA carrier supplementation for recombinant proteins, and acetic acid acidification for hydrophobic peptides requiring low pH solubilisation
NICE obesity guidance recommends evidence-based interventions including dietary change, physical activity, and licensed medications such as orlistat or semaglutide
Not for injection, infusion, or any clinical application
However, PRP has substantially more clinical evidence supporting its use and established safety profiles for numerous applications